Effect of etidronate on urinary calcium / creatinin ratio in postmenopausal women: A prospective, randomized, placebo controlled study
| dc.contributor.author | Küçük, Şenol | |
| dc.contributor.author | Gökdeniz, Remzi | |
| dc.contributor.author | Atmaca, Ruşen | |
| dc.contributor.author | Uryan, İsmail | |
| dc.contributor.author | Buhur , Ali | |
| dc.contributor.author | Taşkın, Ömür | |
| dc.date.accessioned | 2021-10-20T12:57:01Z | |
| dc.date.available | 2021-10-20T12:57:01Z | |
| dc.date.issued | 1999 | |
| dc.department | İnönü Üniversitesi | en_US |
| dc.description.abstract | Abstract: There are both histomorphometric and nonhistomorphometric studies confirming that etidronate reduces bone resorption. In this study, we have examined urinary Calcium/Creatinine ratio (uCA/Cr) as a biochemical marker of bone turnover to show the effectiveness of etidronate and whether it could be used as a follow-up parameter of treatment. Eighty-one postmenopausal women aged 40 to 65 included into the study to investigate the effects of etidronate on uCa/Cr in a prospective, randomised, placebo controlled clinical trial. All necessary criteria matched 81 women were divided into 3 groups at random, each group consisted of 27 patients. Prior to treatment, uCa/Cr was calculated from all subjects 3 hours after drinking 1 liter of water in the morning. Twenty seven (33.3%) women were randomised to oral doses of etidronate (400 mg/day for two weeks followed by drug free period of 10 weeks), twenty seven women to etidronate (400 mg/day for two weeks) plus calcium (1000 mg/day) for the following 10 weeks and twenty seven women to placebo (Fe, 50 mg/day) for 12 weeks. After 12 weeks of treatment, uCa/Cr declined significantly in the etidronate group from 0.118±0.064 to 0.053±0.021, in etidronate+calcium group from 0.08±0.03 to 0.06±0.015 ((p=0.004) and (p=0.005), respectively). In the placebo group no significant change was observed (p=0.03). In conclusion, etidronate is effective in postmenopausal women and the effectiveness of treatment may be followed up by measuring uCa/Cr which is a simple and cheap parameter of determining the effectivensess of etidronate in prevention of osteoporosis. However, since there are contradictory findings concerning uCa/Cr exist, larger clinical and prospective studies should be carried out. | en_US |
| dc.identifier.citation | KÜÇÜK Ş,GÖKDENİZ R,ATMACA R,URYAN İ,BUHUR A,TAŞKIN Ö (1999). Effect of etidronate on urinary calcium / creatinin ratio in postmenopausal women: A prospective, randomized, placebo controlled study. Turkish Journal of Medical Sciences, 29(6), 683 - 687. | en_US |
| dc.identifier.endpage | 687 | en_US |
| dc.identifier.issn | 1300-0144 | |
| dc.identifier.issn | 1303-6165 | |
| dc.identifier.issue | 6 | en_US |
| dc.identifier.startpage | 683 | en_US |
| dc.identifier.trdizinid | 9284 | en_US |
| dc.identifier.uri | https://hdl.handle.net/11616/42365 | |
| dc.identifier.uri | https://search.trdizin.gov.tr/yayin/detay/9284 | |
| dc.identifier.volume | 29 | en_US |
| dc.indekslendigikaynak | TR-Dizin | en_US |
| dc.language.iso | en | en_US |
| dc.relation.ispartof | Turkish Journal of Medical Sciences | en_US |
| dc.relation.publicationcategory | Makale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
| dc.rights | info:eu-repo/semantics/openAccess | en_US |
| dc.title | Effect of etidronate on urinary calcium / creatinin ratio in postmenopausal women: A prospective, randomized, placebo controlled study | en_US |
| dc.type | Article | en_US |
